{"expires": 1766434824, "value": "{\"moat_score\": 0.8, \"reasoning\": \"GILD's high gross margin and operating margin indicate strong pricing power and cost management, while its high ROE suggests efficient use of shareholder capital. However, the high debt/equity ratio is a concern. As a leader in the healthcare sector, GILD's moat is robust due to its portfolio of patented drugs and research capabilities, but debt levels prevent it from being exceptional.\"}"}